Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker

Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer

(2018) Gemma L. Owens et al.   JOURNAL OF IMMUNOTHERAPY

Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management

(2017) Julia J Scarisbrick   Future Oncology

First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors

(2017) Geoffrey I. Shapiro et al.   INVESTIGATIONAL NEW DRUGS

Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody–Drug Conjugate Targeting 5T4

(2017) Jay Harper et al.   MOLECULAR CANCER THERAPEUTICS

Breast cancer: T-DM1 — an important agent in the history of breast cancer management

(2017) Otto Metzger-Filho et al.   Nature Reviews Clinical Oncology

Antibody drug conjugates: lessons from 20 years of clinical experience

(2016) A. W. Tolcher   ANNALS OF ONCOLOGY

Antibody-drug conjugates—an emerging class of cancer treatment

(2016) Nikolaos Diamantis et al.   BRITISH JOURNAL OF CANCER

5T4 oncofoetal antigen: an attractive target for immune intervention in cancer

(2016) Peter L. Stern et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma

(2016) Samuel A. Kerk et al.   CLINICAL CANCER RESEARCH

Antibody-drug conjugates: recent advances in conjugation and linker chemistries

(2016) Kyoji Tsuchikama et al.   Protein & Cell

Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes

(2015) B. Shor et al.   CLINICAL CANCER RESEARCH

Antibody–Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs

(2015) Christopher R. Behrens et al.   MOLECULAR PHARMACEUTICS

In Vitro and In Vivo Evaluation of Cysteine Rebridged Trastuzumab–MMAE Antibody Drug Conjugates with Defined Drug-to-Antibody Ratios

(2015) Penny Bryant et al.   MOLECULAR PHARMACEUTICS

A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy

(2015) Antoine Maruani et al.   Nature Communications

Mild Method for Succinimide Hydrolysis on ADCs: Impact on ADC Potency, Stability, Exposure, and Efficacy

(2014) L. Nathan Tumey et al.   BIOCONJUGATE CHEMISTRY

Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates

(2014) Robert P Lyon et al.   NATURE BIOTECHNOLOGY

Next generation maleimides enable the controlled assembly of antibody–drug conjugates via native disulfide bond bridging

(2014) Felix F. Schumacher et al.   ORGANIC & BIOMOLECULAR CHEMISTRY

Understanding and exploiting 5T4 oncofoetal glycoprotein expression

(2014) Peter L. Stern et al.   SEMINARS IN CANCER BIOLOGY

Naptumomab Estafenatox: Targeted Immunotherapy with a Novel Immunotoxin

(2014) Tim Eisen et al.   Current Oncology Reports

Vaccination of castration-resistant prostate cancer patients with TroVax (MVA–5T4) in combination with docetaxel: a randomized phase II trial

(2013) Richard Harrop et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Drug-conjugated antibodies for the treatment of cancer

(2012) John M. Lambert   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Long-term Tumor Regression Induced by an Antibody-Drug Conjugate That Targets 5T4, an Oncofetal Antigen Expressed on Tumor-Initiating Cells

(2012) P. Sapra et al.   MOLECULAR CANCER THERAPEUTICS

Delineation of a Cellular Hierarchy in Lung Cancer Reveals an Oncofetal Antigen Expressed on Tumor-Initiating Cells

(2011) M. Damelin et al.   CANCER RESEARCH

Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia

(2008) Roberto Stasi et al.   CANCER TREATMENT REVIEWS